---
title: "Kabra Drugs Ltd (524322) — Share Price, Financials & Analysis"
symbol: "524322"
company: "Kabra Drugs Ltd"
canonical: "https://tapetide.com/stocks/524322"
isin: "INE323K01017"
nse_symbol: "KABRADRUGSLTD"
bse_code: "524322"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 47.23
generated_at: "2026-09-13T19:38:48.834Z"
---

# Kabra Drugs Ltd (524322)

Canonical page: https://tapetide.com/stocks/524322

## Company

- **NSE Symbol:** KABRADRUGSLTD
- **BSE Code:** 524322
- **ISIN:** INE323K01017
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** kabradrugs.com

## About

Incorporated in 1989, Kabra Drugs Ltd deals in pharmaceutical products, biological API’s and biochemicals.[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:51:07.964191Z.

- **Market Cap:** ₹47.23 Cr
- **Classification:** Microcap
- **P/E (reported):** 6.3
- **EPS (TTM):** ₹3.2
- **Book Value:** ₹12.49
- **Price to Book:** 1.61
- **Dividend Yield:** 0%
- **ROE:** -4.4%
- **ROCE:** -4.4%
- **Debt to Equity:** 0.03
- **Revenue (yearly):** ₹92.74 Cr
- **Net Income:** ₹4.96 Cr
- **EBITDA:** ₹5.33 Cr
- **52-Week High:** ₹35.52
- **52-Week Low:** ₹15.5
- **RSI (14):** 39.9

## Tapetide Score

- **Score:** 49 / 100
- **Score date:** 2026-09-04
- **Archetype:** Cheap but Weak
- **What it means:** A low multiple sitting on weak financials. Worth establishing what the market is discounting before treating the low valuation as an opportunity — weak fundamentals often justify it.
- **Pillar profile:** Quality: Weak · Valuation: Cheap · Momentum: Falling
- **Percentile:** 43.6 (of 4473 scored stocks)
- **Confidence:** 95%
- **Data coverage:** 90%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 48.1 | 9% |
| growth | 98.9 | 9% |
| momentum | 11.04 | 12% |
| ownership | 50 | 24% |
| quality | 30.59 | 22% |
| valuation | 61.66 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.
- Company has delivered good profit growth of 96.8% CAGR over last 5 years

### Weaknesses

- Company has a low return on equity of 7.79% over last 3 years.
- Company has high debtors of 279 days.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| ebitda margin growth | 93.33% | -103.4% | — | — |
| net income growth | 90.91% | -550.91% | 155% | 97% |
| revenue growth | 30.42% | — | — | — |
| roce | — | -93.53% | -109.52% | 21.53% |
| roe | — | -93.53% | -8.72% | -105.08% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.15 | 19.76 | 30.42 | 35.41 | 46.22 |
| Expenses | 0.13 | 0.11 | 0.37 | 0.55 | 0.4 | 0.53 | 0.24 | 7.67 | 17.72 | 27.99 | 34.07 | 43.43 |
| Operating Profit | -0.13 | -0.11 | -0.37 | -0.55 | -0.4 | -0.53 | -0.24 | -0.52 | 2.04 | 2.43 | 1.34 | 2.79 |
| OPM % | — | — | — | — | — | — | — | -7.27 | 10.32 | 7.99 | 3.78 | 6.04 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0.64 | 0.02 | 0.18 | 0.18 | 0.11 | 0.08 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0 | 0.01 | 0.01 | 0.02 | 0.02 |
| Profit before tax | -0.13 | -0.11 | -0.37 | -0.55 | -0.4 | -0.53 | 0.39 | -0.5 | 2.21 | 2.6 | 1.42 | 2.84 |
| Tax % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.74 | 1.54 | 25.35 | 25.35 |
| Net Profit | -0.13 | -0.11 | -0.37 | -0.55 | -0.4 | -0.54 | 0.39 | -0.5 | 1.84 | 2.57 | 1.06 | 2.12 |
| EPS in Rs | -0.3 | -0.25 | -0.84 | -1.25 | -0.4 | -0.54 | 0.16 | -0.21 | 0.78 | 1.08 | 0.45 | 0.89 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 93 | 132 |
| Expenses | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 87 | 123 |
| Operating Profit | -1 | 0 | 0 | 0 | 0 | 0 | -1 | -2 | 5 | 9 |
| OPM % | -57 | — | -150 | — | — | -3400 | — | — | 6 | 7 |
| Other Income | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -2 | 0 | 0 | 0 | 0 | 0 | -1 | -1 | 6 | 9 |
| Tax % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | — |
| Net Profit | -2 | 0 | 0 | 0 | 0 | 0 | -1 | -1 | 5 | 8 |
| EPS in Rs | -5.38 | -0.36 | -0.14 | -0.41 | -0.43 | -0.77 | -1.69 | -0.46 | 2.09 | 3.2 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 24 | 24 |
| Reserves | -2 | -4 | -4 | -4 | -5 | -5 | -5 | -3 | 1 | 6 |
| Borrowings | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 1 |
| Other Liabilities | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 2 | 0 | 56 |
| Total Liabilities | 6 | 2 | 1 | 1 | 1 | 1 | 1 | 5 | 25 | 86 |
| Fixed Assets | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 4 | 2 | 1 | 1 | 1 | 1 | 1 | 5 | 25 | 85 |
| Total Assets | 6 | 2 | 1 | 1 | 1 | 1 | 1 | 5 | 25 | 86 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5 | -9 |
| Cash from Investing Activity | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 |
| Cash from Financing Activity | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 3 | 23 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 19 | -11 |
| Free Cash Flow | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | -5 | -10 |
| CFO/OP | 73 | 10 | 138 | 100 | 167 | 72 | 100 | 28 | 274 | -173 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 141 | 254 | -11406 | — | — | — | — | — | — | 279 |
| Inventory Days | 17 | 0 | 0 | — | — | — | — | — | — | 0 |
| Days Payable | 97 | — | — | — | — | — | — | — | — | — |
| Cash Conversion Cycle | 61 | 254 | -11406 | — | — | — | — | — | — | 279 |
| Working Capital Days | 34 | -28 | -912 | — | — | — | — | — | — | 66 |
| ROCE % | 7 | -44 | -19 | -9 | -27 | -29 | -53 | -43 | -8 | 21 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 95.95% | 95.92% | 95.73% | 95.85% | 96.19% | 96.12% | 95.94% | 95.61% | 95% | 91.43% | 90.92% | 90.69% |
| Others | 4.05% | 4.08% | 4.27% | 4.15% | 3.81% | 3.88% | 4.06% | 4.39% | 5% | 8.57% | 9.08% | 9.31% |
| No. of Shareholders | 7415 | 7396 | 7364 | 7336 | 7367 | 7343 | 7435 | 7449 | 8098 | 8862 | 9185 | 9680 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 3 / 6 / 10

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 20.12 | Buy |
| EMA (10) | 20.47 | Buy |
| SMA (20) | 20.89 | Sell |
| EMA (20) | 20.99 | Sell |
| SMA (50) | 22.29 | Sell |
| EMA (50) | 22.12 | Sell |
| SMA (100) | 23.31 | Sell |
| EMA (100) | 23.25 | Sell |
| SMA (200) | 26.2 | Sell |
| EMA (200) | 23.11 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 44.53 | Neutral |
| MACD (12,26,9) | -0.72 | Buy |
| Stochastic (14,3,3) | 35.01 | Neutral |
| ADX (14) | 11.79 | Neutral |
| Williams %R (14) | -50.75 | Neutral |
| ATR (14) | 1.62 | High Volatility |
| ROC (12) | -1.34 | Sell |
| Stoch RSI (14) | 96.28 | Sell |
| UO (7,14,28) | 41.57 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-09 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4eae151f-469c-4227-a71a-410791fff806.pdf) |
| 2026-09-08 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2a8f8163-f755-4972-8879-f90803c7c00b.pdf) |
| 2026-09-07 | [Submission Of Notice Of Annual General Meeting Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligation And Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ced4f116-3137-40ae-a050-a55507d1cf04.pdf) |
| 2026-09-03 | [Book Closure And Schedule Of Events For E-Voting.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dd6cdd9f-3731-4a2e-a77f-00104a881e79.pdf) |
| 2026-09-02 | [Board Meeting Outcome for Outcome Of Board Meeting Held On 02Nd September 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6a94c12e-aebd-47aa-a984-05fd834d1ba5.pdf) |
| 2026-09-02 | [Appointment Of Secretarial Auditor Of The Company](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=688ecd50-0b15-4442-bf6e-d27827ca1097.pdf) |
| 2026-09-02 | [Appointment Of Internal Auditor Of The Company](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b031d84f-8d09-4208-9561-10970a17ade8.pdf) |
| 2026-08-29 | [Announcement under Regulation 30 (LODR)-Change in Registered Office Address](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=221331c8-f196-4b65-868f-711ad7629d46.pdf) |
| 2026-08-27 | [Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 02Nd September 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b0cd7eb9-770e-4cce-936e-48609b5562cd.pdf) |
| 2026-08-18 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0c532e57-e340-4353-8bbd-6218155418d0.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-12 | [Financial Results For The Quarter Ended 30Th June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8b2faf95-95d4-4d8f-bfba-3f4ab736e127.pdf) |
| 2026-05-29 | [Financial Results For Quarterly & Year Ended 31St March 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=41848b08-d546-4335-a40b-a27b8aace7aa.pdf) |
| 2026-02-13 | [Financial Results For The Quarter Ended 31St December 2025 Under Regulation 33 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e5fcfb29-d271-487e-95e0-e6fd8147d5fa.pdf) |
| 2025-11-13 | [Financial Results For The Quarter Ended 30 Th September 2025 Under Regulation 33 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=27f776ee-4c35-493d-a699-9e0675404b8a.pdf) |
| 2025-08-14 | [Financial Results For The Quarter Ended June 30 2025 Under Regulation 33 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=64441e85-c151-47f2-a2ce-664411440a86.pdf) |
| 2025-05-30 | [Audited Financial Result For Quarter And Year Ended 31St March 2025 Pursuant To Regulation 33 Of The SEBI (LODR) Regulations 2015.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cbe34371-c94b-46f7-a631-24c18d908a66.pdf) |
| 2025-02-14 | [Financial Results For The Quarter Ended December 31 2024 Under Regulation 33 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a8f271c8-5b53-4f96-93ed-9f277f4099f8.pdf) |
| 2024-11-14 | [Financial Results For The Quarter And Half Year Ended September 30, 2024 Under Regulation 33 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=60b8e7ed-aa9d-45c6-8d05-bcccb6bda118.pdf) |
| 2024-08-14 | [Financial Results For The Quarter Ended June 30, 2024 Under Regulation 33 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=669771f4-ef67-4a7f-b8f6-7d40dc41f1ae.pdf) |
| 2024-05-30 | [Audited Financial Result For Quarter And Year Ended 31St March, 2024 Pursuant To Regulation 33 Of The SEBI (LODR) Regulations, 2015.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3abbb92f-f2ed-4ac7-afba-d7ca62f4ccdd.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9h - Kabra Drugs appointed Ms. Monam Kapoor as additional non-executive independent director on 21 April 2026. | [Announcement under Regulation 30 (LODR)-Change in Directorate 9h - Kabra Drugs appointed Ms. Monam Kapoor as additional non-executive independent director on 21 April 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/1968ed1d-fa58-436c-b4ba-bec515b041b7.pdf) |
| 9h - Board approved new objects, independent director appointment, and postal ballot for name and object changes. | [Board Meeting Outcome for Outcome Of Board Meeting Held On 21St April 2026 9h - Board approved new objects, independent director appointment, and postal ballot for name and object changes.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/a8899a5e-19cd-493f-8a9b-d6dee86b3e76.pdf) |
| 8h - EGM on 9 April 2026 to approve shipbuilding contract modification and DPCCL guarantee for WSPL loan. | [Outcome Of Board Meeting. 8h - EGM on 9 April 2026 to approve shipbuilding contract modification and DPCCL guarantee for WSPL loan.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/ad2a63c5-937f-4b5d-ba6d-bb20ba882199.pdf) |
| 8h - Board approved EGM on 9 April 2026 to seek shareholder approval for shipbuilding contract modification and corporate guarantee to WSPL. | [Board Meeting Outcome for Outcome Of Board Meeting. 8h - Board approved EGM on 9 April 2026 to seek shareholder approval for shipbuilding contract modification and corporate guarantee to WSPL.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/5350a1f7-044e-4d52-b7ca-216febf1cd9a.pdf) |
| 8 May - Postal ballot seeks renaming to Aanjaay Industries and adding businesses in drones, energy, steel, healthcare, AI. | [Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 8 May - Postal ballot seeks renaming to Aanjaay Industries and adding businesses in drones, energy, steel, healthcare, AI.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/53911fe3-98ef-406b-9b70-1a7147dd92fd.pdf) |
| 8 Jan - DPCCPL to discontinue Deltin Zuri Goa casino effective Jan 9, 2026; turnover Rs.15.51 crore, minimal impact. | [Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 8 Jan - DPCCPL to discontinue Deltin Zuri Goa casino effective Jan 9, 2026; turnover Rs.15.51 crore, minimal impact.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/aaf6d373-709e-42bc-99e8-19d333a6a128.pdf) |
| 8 Jan - Board meeting 15 Jan 2026 to approve unaudited standalone and consolidated Q3 and 9M results ended 31 Dec 2025. | [Board Meeting Intimation for Un-Audited Financial Results Of The Company For The Quarter And Nine Months Ended 31.12.2025 8 Jan - Board meeting 15 Jan 2026 to approve unaudited standalone and consolidated Q3 and 9M results ended 31 Dec 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5ee100b1-1de3-4a37-91a1-b334a149ede6.pdf) |
| 7 Mar - Board approved name change to Aanjaay Industries and strategic defence JV with PT Bhinneka Dwi Persada, Indonesia. | [Board Meeting Outcome for Outcome Of Board Meeting Held On 07 Th March 2026, As Per Regulation 30 Of SEBI (LODR) Regulations, 2015. 7 Mar - Board approved name change to Aanjaay Industries and strategic defence JV with PT Bhinneka Dwi Persada, Indonesia.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3f395f35-e8cb-4804-8897-a16b2e53597f.pdf) |
| 7 Apr - Submitted Regulation 74(5) compliance certificate for quarter ended 31 March 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Apr - Submitted Regulation 74(5) compliance certificate for quarter ended 31 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/915307b0-c687-4023-86d7-04eb7353b18d.pdf) |
| 6 May - Board approved phased pharma expansion, AI-defence R&D facility in Chennai, SCOMET license process, and appointed independent consultant. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 6 May - Board approved phased pharma expansion, AI-defence R&D facility in Chennai, SCOMET license process, and appointed independent consultant.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/a05370ee-558e-4c0e-9daa-f1edd7a7dea6.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2012 from nse](https://archives.nseindia.com/annual_reports/AR_DELTACORP_2011_2012_31122012034949.zip) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4445b54d-c129-4bdf-925c-0a1b1b19ad0f.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2ae9d627-2d3a-48a0-b1b3-a29bc6797698.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/72ed2019-7cf4-42b2-a284-f4b8dd409e3f.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2f5caafe-c313-4be2-b6c1-7d46a4759e60.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/05c77393-f69d-45f8-804f-e65ebcb43010.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/142765fb-1979-422f-a888-9babfc5fa8eb.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/532848/74049532848.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/524322/77346524322.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/532848/69143532848.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Oct 2022 | [Concall - Oct 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/45a5514f-9e10-4004-b787-a093bfac4307.pdf) |
| Jul 2023 | [Concall - Jul 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b930f232-d617-482a-8d16-deb1a9d2a4dd.pdf) |
| Jul 2022 | [Concall - Jul 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8a251e2d-147c-4615-87d8-3529c5d9f8e2.pdf) |
| Jan 2024 | [Concall - Jan 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cd55c95a-dec6-41a9-b511-59cf950ebf6d.pdf) |
| Jan 2023 | [Concall - Jan 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/879e9761-d7a3-40df-bfb1-99a0898ba2c1.pdf) |
| Feb 2017 | [Concall - Feb 2017](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=A55D8C0B_0263_49BA_9884_D4BFCA81924F_104652.pdf) |
| Apr 2023 | [Concall - Apr 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/47817bdf-e27d-4530-8cd6-4a5e513f029c.pdf) |
| Apr 2022 | [Concall - Apr 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/dd0ade7d-4fb7-4e26-b707-63ef6cf0c1e7.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:38:48.834Z.